Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

Group 1 - AngioDynamics (ANGO) is currently outperforming its peers in the Medical sector, with a year-to-date return of approximately 0.9%, while the average return for the Medical group is a loss of about 7.8% [4] - The Zacks Rank for AngioDynamics is 1 (Strong Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 26% in the past quarter [3] - AngioDynamics belongs to the Medical - Instruments industry, which has an average loss of 14% year-to-date, further highlighting its strong performance relative to its industry peers [5] Group 2 - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector, with a year-to-date increase of 14.7% [4] - The consensus estimate for ANIX's current year EPS has risen by 10.9% over the past three months, and it holds a Zacks Rank of 2 (Buy) [5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has experienced a decline of 11.4% this year, indicating that ANIX is also performing well within its industry [6]